Prognostic significance of long non coding maternally expressed gene 3 in pediatric acute myeloid leukemia

Abstract

The purpose of this study was to evaluate the correlation of long non-coding RNA maternally expressed gene 3 (Lnc-MEG3) with disease features, treatment response, and survival in pediatric acute myeloid leukemia (AML) patients. Among 92 de novo pediatric AML patients (before treatment and after 1 course of induction) and 40 controls, bone marrow mononuclear cells were obtained. Then, Lnc-MEG3 expression was determined by reverse transcription quantitative polymerase chain reaction. After 1 course of standard induction therapy of pediatric AML patients, complete remission (CR) was assessed. Furthermore, event-free survival (EFS) and overall survival (OS) were determined according to follow-up data. Lnc-MEG3 was reduced in pediatric AML patients compared with controls. In pediatric AML patients, Lnc-MEG3 was correlated with French-American-Britain subtypes and lower Chinese Medical Association risk stratification, while it was not associated with cytogenetic features, FLT3-ITD mutation, CEBPA mutation, NPM1 mutation, WT1 mutation, or National Comprehensive Cancer Network risk stratification. After 1 course of treatment, Lnc-MEG3 exhibited an up-regulation trend. Furthermore, Lnc-MEG3 was of no difference before treatment between patients with and without CR, while elevated Lnc-MEG3 and change of Lnc-MEG3 after 1 course of treatment were associated with increased CR rate. Additionally, increased Lnc-MEG3 expression before treatment was associated with longer EFS but not OS, while enhanced Lnc-MEG3 expression after 1 course of treatment was correlated with both prolonged EFS and OS. Lnc-MEG3 may have clinical significance as a biomarker for assisting with disease management, treatment optimization, and prognosis improvement in pediatric AML patients.

Intelligent structure prediction and visualization analysis of non-coding RNA in osteosarcoma research

“…lnc-meg3 may be Biomarkers associated with acute myeloid leukemia ( 79 ). As a biomarker, NRC-MEG3 is useful for disease management, treatment optimization, and improved prognosis in pediatric AML ( 80 ) and cALL ( 81 ) patients. The low expression of circ-ITCH is substantially connected with the aggressive clinicopathological characteristics and poor prognosis of various malignancies, according to research by Xiao-Dong Sun and Da-Wei Sun et al ( 82 ).…”

Diagnostic and Therapeutic Implications of Long Non-Coding RNAs in Leukemia

“…In AML, it was shown that increased expression of MEG3 is a reliable molecular marker of favorable prognosis, both in pediatric and adult patients. In adult de novo AML patients, high MEG3 expression was independent predictor for longer DFS and OS [128], while in pediatric de novo AML patients increased MEG expression was associated with prolonged OS [133,134]. High MEG3 expression in AML patients after induction therapy was also associated with better DFS and OS, indicating that it could be used as a marker for the prediction of therapy response.…”

MEG3 in hematologic malignancies: from the role of disease biomarker to therapeutic target

“…MEG3 downregulation has been observed in both clinical samples and cell lines of leukemia. A line of studies reported that in acute myeloid leukemia (AML), the expression of MEG3 was reduced in bone marrow samples, peripheral blood mononuclear cells (PBMCs), as well as cell lines [32][33][34][35][36][37][38][39]41,42,[53][54][55][56]. Acute promyelocytic leukemia (APL) is a unique subtype of AML characterized by specific genetic defects, typically involving the fusion gene PML/RARα [57].…”